Biotech company Heligenics has introduced a new precision genetic test to choose among drugs for the treatment of breast cancer.
The new genetic test helps select among three drugs approved by the US Food and Drug Administration (FDA) for breast cancer.
The company began with the drugs, Tykerb, Nerlynx and Tukysa.
Heligenics stated that there are more than 10,000 potential mutations in a cancer gene and it is difficult to identify which one produces resistance.
